News & Updates

A booster dose of the mRNA-based BNT162b2 vaccine provides more robust antibody responses to SARS-CoV-2, including the Omicron BA.1 and BA.2 variants, than the inactivated CZ02 vaccine, but three doses of either vaccine are equally effective in reducing the risk of severe or fatal COVID-19, according to new local data presented at the 26th Hong Kong Medical Forum (HKMF).

A large study by the US National COVID Cohort Collaborative (N3C) has identified factors associated with the risk of severe disease among children with SARS-CoV-2 infection as well as factors tied to an increased risk of multisystem inflammatory syndrome in children (MIS-C) as compared to acute COVID-19.

SER-109, an investigational oral microbiome therapeutic, achieves superiority over placebo in reducing recurrent Clostridioides difficile infection (CDI) rates, according to updated findings from the phase III ECOSPOR-III trial.

For patients with a history of cancer, exercising appears to lower the risk of contracting COVID-19 infection, according to a study.

Acceptance rates of COVID-19 vaccines have remained unchanged among unvaccinated pregnant women following national recommendations, with nearly one-third of patients seeing the vaccine as something harmful to their pregnancy, according to a study.

Oral tebipenem pivoxil hydrobromide appears to be as good as intravenous ertapenem in the treatment of patients with complicated urinary tract infection (UTI) and acute pyelonephritis, with the two having a similar safety profile, according to data from a phase III study.